These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38263159)

  • 1. "Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose.
    Aquizerate A; Rousselet M; Cochard A; Guerlais M; Gerardin M; Lefebvre E; Duval M; Laforgue EJ; Victorri-Vigneau C
    Harm Reduct J; 2024 Jan; 21(1):20. PubMed ID: 38263159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study.
    Duval M; Aquizerate A; Jaulin E; Rousselet M; Kuhn E; Guilleminot A; Nicolleau I; Pele S; Herault T; Artarit P; Soulidou-Jacques E; Laforgue EJ; Victorri-Vigneau C
    Therapie; 2024 Jul; ():. PubMed ID: 39174452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19.
    Potaka KL; Freeman R; Soo D; Nguyen NA; Sim TF; Moullin JC
    BMC Emerg Med; 2022 Apr; 22(1):62. PubMed ID: 35397487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.
    Nolan S; Buxton J; Dobrer S; Dong H; Hayashi K; Milloy MJ; Kerr T; Montaner J; Wood E
    Public Health Rep; 2017; 132(5):563-569. PubMed ID: 28750193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
    Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
    Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.
    Holmén E; Warnqvist A; Kåberg M
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efforts to Improve Naloxone Co-Prescription for Patients With Cancer Pain at Risk of Opioid Overdose.
    Amaram-Davila J; Reddy A; Arthur J; Narayanan S; Gogineni M; Mallipeddi T; De Moraes AR; Maddi R; Shelal Z; Urbauer D; Chen M; Bruera E
    J Palliat Med; 2023 Jul; 26(7):969-973. PubMed ID: 37074064
    [No Abstract]   [Full Text] [Related]  

  • 16. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard' associated with naloxone supply.
    Tse WC; Djordjevic F; Borja V; Picco L; Lam T; Olsen A; Larney S; Dietze P; Nielsen S
    Int J Drug Policy; 2022 Feb; 100():103513. PubMed ID: 34798434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a take-home naloxone program at an urban academic emergency department.
    Eswaran V; Allen KC; Cruz DS; Lank PM; McCarthy DM; Kim HS
    J Am Pharm Assoc (2003); 2020; 60(6):e324-e331. PubMed ID: 32690447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?
    Marino R; Landau A; Lynch M; Callaway C; Suffoletto B
    Addiction; 2019 Sep; 114(9):1575-1581. PubMed ID: 31013394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.
    Natale I; Harvey C; Wood P; Anderson K
    Qual Res Med Healthc; 2023 Jul; 7(2):10868. PubMed ID: 37692452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.